Everest Medicines launches clinical trial for personalized mRNA cancer vaccine EVM16
Everest Medicines Limited (HKEX: 1952.HK) has announced the launch of an Investigator-Initiated Clinical Trial (IIT) for its innovative personalized mRNA cancer vaccine, EVM16. The trial, designated EVM16CX01, is set to take place at Peking University Cancer Hospital and Fudan University’s Cancer Hospital. This groundbreaking study will be the first-in-human (FIH) trial for EVM16, designed to […]